Introduction
Anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), occurring more frequently than in the general population [1] [2] [3] [4] or patients with other chronic diseases such as hypertension, diabetes, cancer, or musculoskeletal disorders. 5, 6 Th eir presence is associated with worse outcomes of COPD, and increased morbidity, mortality, disability, and health care expenditure. [6] [7] [8] In spite of this, both anxiety and depression are frequently overlooked and undertreated in patients with COPD, 9 and symptoms of anxiety and depression can overlap signifi cantly, as well as overlap with COPD symptoms. 7, 10 Comorbid depressive disorders that may occur in patients with COPD include major depressive disorder, dysthymias (chronic depressive symptoms of mild severity), and minor depression. 11 Depressive disorders are characterized by feelings of sadness, emptiness, and/or irritability, along with cognitive and somatic symptoms, which have a detrimental eff ect on the patient's ability to function. 11 Anxiety disorders include generalized anxiety disorder (GAD), phobias, and panic disorders. 11 Th e main features of anxiety disorders, such as excessive fear and anxiety, may be accompanied by behavioral disturbances related to these symptoms, such as panic attacks and avoidance. 11, 12 Th e reported prevalence of depression in COPD varies widely between studies, owing to diff erences in sampling methods and degrees of illness severity used in assessment of depression 6 ; rates have been reported to range from 10% to 42% in patients with stable COPD, 6, 13 and from 10% to 86% in patients with acute COPD exacerbation.
14 Individuals with severe COPD are twice as likely to develop depression than patients with mild COPD. 10 Prevalence rates for clinical anxiety in COPD range from 13% to 46% in outpatients and 10% to 55% among inpatients. GAD, panic disorders, and specifi c phobias are reported most frequently. 15 Patients with COPD are 85% more likely to develop anxiety disorders compared with matched controls without COPD, 4 and panic disorder is reported with a prevalence that is up to 10-fold higher than in the general population. 16 Global prevalence rates of anxiety and depression are 1.8-and 1.4-fold higher in women than men, respectively 17 ; the same gender diff erence is observed in patients with COPD. 6 Th e higher prevalence rates of anxiety and depression in women are thought to be a result of sex diff erences in brain structure, function, and stress responses, as well as diff erences in exposure to reproductive hormones, social constraints, and experiences between women and men. 18 However, psychologic comorbidity is an issue for both men and women with COPD, so it is important that clinicians are vigilant in recognizing anxiety and depression in both sexes, and are careful not to underestimate the burden in the male patient population.
It is also important to note that depression and anxiety often occur simultaneously in patients with COPD, with prevalence estimates of 26% to 43%. 9, 19, 20 COPD patients with both depression and anxiety are at a heightened risk of suicidal ideation, increased physical disability, and chronic depressive symptoms versus those with either disorder alone. 10, 15 It is therefore important that comorbid anxiety and depression is not overlooked in patients with COPD.
Ensuring that anxiety and depression are recognized and treated eff ectively in patients with COPD is essential for optimizing outcomes. Primary care practitioners are well placed to diagnose anxiety and depression, and to ensure these conditions are suitably managed alongside treatments of COPD.
Potential mechanisms of anxiety and depression in COPD
Growing evidence suggests that the relationship between mood disorders-particularly depression-and COPD is bidirectional, meaning that mood disorders adversely impact prognosis in COPD, whereas COPD increases the risk of developing depression. 21 For example, in a study of 60 stable patients with COPD, elevated dyspnea and reduced exercise capacity were the predominant mechanisms leading to anxiety and depression symptoms associated with the condition. 22 In addition, the risk of new-onset depression was increased in COPD patients with moderate-to-severe dyspnea in a 3-year follow-up study. 23 Conversely, depression has been shown to be a signifi cant risk factor for disabling dyspnea (modifi ed Medical Research Council score ≥2) in patients with COPD. 24 COPD can lead to feelings of hopelessness, social isolation, reduced physical functioning, and sedentary lifestyle, all of which are associated with an increased level of depressive symptoms. 25 Similarly, inadequate social support increases the risk of anxiety in patients with COPD. 26 Th erefore, ensuring that patients with COPD have highquality support is very important for reducing anxiety and depressive symptoms. 27 Th e exact mechanisms for the association between mood disorders and COPD remain unclear. 7, 10 Research to date indicates that the relationship between depression and impaired pulmonary function may be partly mediated by chronic infl ammation 7, 10 ; systemic infl ammation has been associated with other comorbidities of COPD (eg, muscle wasting and osteoporosis), 28 and emerging data appear to show that proinfl ammatory cytokines partly mediate the association between depressive symptoms and pulmonary function. 29 Smoking and hypoxemia may also infl uence the prevalence of depression in COPD, but symptom severity and impaired quality of life remain the most important determinants. 6, 30 Clinical studies have demonstrated that a number of patient-related factors, including female gender, younger age, current smoking, greater severity of airfl ow limitation, and lower socioeconomic status, are associated with a higher prevalence and/or increased risk of depression and/or anxiety in COPD. 3, 4, 30, 31 Frequent episodes of rehospitalization, and comorbidities such as hypertension, arthritis, cancer, and heart disease, have been found to increase the risk of anxiety and depression in patients with COPD. 3, 32 Risk of anxiety has been shown to increase with greater dyspnea severity. 4 Pain, a frequently overlooked symptom in COPD, has been shown to be associated with symptoms of both anxiety and depression in patients with COPD. 33 Th is is driven by worsened quality of life and sleep quality, decreased physical activity, and an increased fear of movement that occur as a result of pain.
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The impact of anxiety and depression in COPD
Comorbid anxiety and depression have a signifi cant detrimental impact on morbidity and mortality in patients with COPD. Both disorders have been associated with an increased risk of death in COPD. 13, [35] [36] [37] Indeed, of 12 comorbidities proposed to be predictors of mortality in a cohort of 187 female outpatients with COPD, anxiety was associated with the highest risk of death. 35, 36 In addition, patients with COPD and anxiety and/or depression have a higher risk of COPD exacerbations, 4, 8, 23, 36, [38] [39] [40] hospitalization, 41, 42 rehospitalization, 14, 36, 43 longer hospital stays, 37, 41, 44 and mortality after exacerbations, 14,36,41 compared with patients without these comorbidities. Patients with COPD who have elevated anxiety symptoms also often experience their fi rst hospitalization earlier in the natural course of COPD than those without anxiety. 36 Psychologic comorbidities are also associated with worse lung function, dyspnea, and respiratory symptom burden in patients with COPD. 37, 40 Patients with COPD and anxiety are more likely to experience greater dyspnea at an earlier stage of disease than those without anxiety.
36 Persistent smoking at 6 months after hospitalization for an acute exacerbation of COPD is also more likely to be seen in patients with depression. 37 Patient-centered outcomes are worse in COPD patients with mood disorders. Both anxiety and depression have been
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shown to correlate with signifi cantly reduced health-related quality of life (HRQoL), poorer physical health status, functional limitations, and reduced exercise capacity. 4, 23, 37, 40, 45 Th e presence of either anxiety or depression at baseline has been shown to correlate with reduced HRQoL at 1-year follow-up, but depression appears to be the stronger predictor of low future HRQoL than anxiety. 45 Additionally, mood disorders-particularly depression-reduce physical activity in patients with COPD. 46, 47 Emotional responses to COPD symptoms, such as dyspnea, can further decrease activity and worsen deconditioning, resulting in a downward spiral of reduced inactivity, social isolation, fear, anxiety, and depression. 48 COPD patients with any comorbidity exhibit lower rates of medication adherence than those without comorbidities. [49] [50] [51] Clinical studies have demonstrated that anxiety and depression are signifi cant predictors of poor adherence to COPD interventions, including pulmonary rehabilitation (PR). [51] [52] [53] [54] [55] Nonadherence to COPD therapies is associated with poor clinical outcomes, including higher hospitalization rates and increased emergency department visits, and increased costs. 56, 57 Health care expenditure, in terms of both specifi c COPD-related costs and general "all-cause" costs, is signifi cantly higher in COPD patients with anxiety and/or depression than in those without. 8 
Diagnosis of anxiety and depression in patients with COPD
Th e underdiagnosis and undertreatment of anxiety and depression in this population is common and can adversely aff ect patient outcomes. 6, 7, 9, 10, 58 Hence, it is crucial that anxiety and depression are identifi ed and more eff ectively managed in clinical practice. 10 Primary care practitioners are the main point of contact for many patients with COPD, 6, 59, 60 and so can play a key role in screening for and early identifi cation of anxiety and depression. However, detection of mood disorders by primary care practitioners is challenging for several reasons. Th ese include the lack of a standardized approach in diagnosis, and inadequate knowledge or confi dence in assessing psychological status (particularly given the number of strategies available for screening patients for mood disorders), 6 as well as factors associated with time constraints, such as competing agendas, duration of visits, and high patient load. 6, 61 Furthermore, system-level barriers, such as lack of electronic medical records and adequate health insurance, as well as any communication gaps between primary care and mental health care, may hinder the detection and management of anxiety and depression. 6 In addition, patients themselves may have a limited understanding of these comorbidities, or may be hesitant to discuss symptoms of anxiety or depression with their primary care practitioner owing to stigma around mental illness. 6 Patients with COPD should be screened and assessed for anxiety and depression, and the United States Preventive Services Task Force recommends that clinicians screen for depression in all adults. 6, 62 Th ere are several validated screening tools suitable for clinical use:
• Anxiety Inventory for Respiratory (AIR) Disease scale: a brief, easy-to-use tool for screening and measuring anxiety in COPD. 63, 64 It is a self-administered scale, and takes approximately 2 minutes to complete. Th e AIR scale is responsive to PR. 64 • COPD Anxiety Questionnaire (CAF): a reliable tool for early identifi cation of COPD-related anxiety.
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• Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Health Questionnaire (PHQ; available at: http://www.phqscreeners.com/selectscreener/): the PRIME-MD comprises 26 yes/no questions on the 5 most common psychiatric disorders, including depression and anxiety. 66, 67 Th is is not a diagnostic tool, but a high number of positive responses from a patient in any given module indicates that they require further clinical evaluation.
• PHQ-2 and PHQ-9 (TABLE 1; PHQ-9 available at http://www.phqscreeners.com/select-screener/): widely-used self-administered 2-and 9-item versions of the PRIME-MD, specifi c to depression; similarly, the 3-item PHQ-3 is available for anxiety assessment (TABLE 2) . 6, 67, 68 In a study investigating tools used by family physicians in England to assess depression, over 75% used PHQ-9.
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• Generalized Anxiety Disorder 7-item (GAD-7) scale:
an effi cient, self-report scale that scores 7 common anxiety symptoms and can be used for screening and severity assessment of GAD in clinical practice.
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• Hospital Anxiety and Depression Scale (HADS) and General Health Questionnaire-version 20 (GHQ-20): both can be used to screen for psychologic distress in patients with COPD.
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• Th e Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI): two 21-item self-report questionnaires that are widely used in the United States to evaluate anxiety and depression. 72 In addition to specifi c anxiety and depression questionnaires (TABLES 1 and 2) , more general COPD assessments tools, such as the COPD Assessment Test and the COPD Clinical Questionnaire, also incorporate questions that may be indicative of symptoms of these comorbidities in patients with COPD.
Management of anxiety and depression in COPD
Even though anxiety and depression are among the most common and burdensome comorbid conditions in COPD, less than one-third of patients with these comorbidities receive eff ective intervention. 6, 10 Primary care providers have an excellent opportunity to impact this care gap.
It is important that all health care professionals involved in the care of patients with COPD are vigilant for anxiety and depressive symptoms, as well as the possibility of a major anxiety or depressive disorder. Communication with other multidisciplinary team members is central to ensuring appropriate psychiatric treatment in patients with COPD, particularly sharing key information about medication history, warning signs of depression and anxiety, and any indication of suicide ideation. 74 Referral to palliative care teams can also help to manage these psychological comorbidities in patients with severe COPD at advanced stages. 75 As in non-COPD patients, comorbid depression and anxiety may be treated with nonpharmacologic and/or pharmacologic interventions (FIGURE 1).
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Nonpharmacologic interventions
Evidence to date suggests that nonpharmacologic interventions such as behavioral therapy are as eff ective as antidepressants, and may be preferred by patients with mood disorders. 12 Cognitive behavioral therapy (CBT), which is typically administered by psychologists/psychiatrists, may be eff ective in treating COPD-related anxiety and depression, especially in conjunction with exercise and education. 12, 76, 77 Individualized or group CBT is the treatment of choice for addressing thinking patterns that contribute to anxiety and depression to change a patient's behavior and emotional state. 76 PR programs involve several components, including aerobic exercise, lung function training, and psycho-education. 62, 76 PR is suitable for most patients with COPD, and provides multiple benefi ts, including reduced hospitalizations in patients who have had a recent exacerbation, and improved dyspnea, exercise tolerance, and health status in patients with stable disease, 62 as well as clinically and statistically signifi cant improvements in depression and anxiety, irrespective of age. 7, 78, 79 Exercise-based forms of PR appear to be the most eff ective for reducing mood symptoms, 12, 76 and incorporating psychotherapy may also improve psychologic outcomes. 80 Stress reduction (relaxation) therapy aims to reduce anxiety-related physiologic changes, and includes a variety of techniques (eg, breathing exercises, sequential muscle relaxation, hypnosis, mindfulness meditation), some of which may be included in PR or used alongside other treatments (eg, CBT). 76 Limited data indicate that such therapy may be benefi cial for reducing anxiety and depression, as well as respiratory symptoms and dyspnea, in patients with COPD. 12, 76 Self-management techniques improve clinical outcomes in patients with COPD, but data on the management of depression or anxiety are inconclusive. 7, 12 A minimal, home-based, nurse-led, psycho-educational intervention was designed to encourage more open-ended, descriptive discussions of thoughts, emotions, behaviors, and bodily sensations in patients with COPD. 81 Th e intervention, which involved nurses attending a 1-hour face-to-face session in the patients' homes with a 15-minute telephone "booster" session 2 weeks later, helped patients with advanced COPD to self-manage their condition and provide relief from anxiety. 81, 82 However, it should be noted that there is currently a lack of high-quality data evaluating psychologic interventions in the COPD population. 83 In addition, it is important that caregivers are supported in the management of patients with COPD and comorbid anxiety and/or depression; areas in which caregivers can be assisted in their role may include disease education and counseling, where appropriate. 84 Given that smoking cessation is a key recommendation for patients with COPD, 44, 62 practitioners should be aware that patients with comorbid depression and anxiety may experience greater diffi culty in smoking cessation, and worsened mood during nicotine withdrawal. 44 Clinicians should therefore carefully monitor current smokers with 
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COPD and comorbid depression/anxiety (using the tools described previously 63, 68, 70, 71 ) when they are attempting to quit smoking.
Pharmacologic interventions
Pharmacologic therapy of anxiety and depression has so far only been investigated in patients with COPD in small studies. 76 However, the available evidence does not indicate that COPD patients with anxiety and depression should be managed any diff erently from individuals without COPD. 62 As such, pharmacologic interventions are particularly important for patients with acute or severe anxiety or depression.
Antidepressant agents are categorized according to their mechanism of action, and most commonly include selective serotonin-reuptake inhibitors (SSRIs), selective norepinephrine-reuptake inhibitors, bupropion (a norepinephrine-and dopamine-reuptake inhibitor; also approved for smoking cessation 85 ), and mirtazapine (a norepinephrine and serotonin modulator), among others. 86 SSRIs are the current fi rstline drug treatment for depression, and have been shown to signifi cantly improve depression and anxiety in patients with COPD in some, but not all, trials published to date. 76 However, it is important to note that a diagnosis of bipolar disorder must be ruled out before initiating standard antidepressant therapy. 87 In addition to antidepressants, atypical antipsychotics have also been shown to be useful for treating anxiety, either as monotherapy or combination therapy, and possibly as an adjunctive therapy for the management of depression. 88, 89 Primary care practitioners can refer to existing guidelines on the management of anxiety and depression in patients with COPD, 86, 90 while taking certain factors into consideration. Any pharmacologic management strategy for the treatment of COPD may increase the risk of drug-drug or drugdisease interactions. 76 F or example, it is important to avoid medications that cause respiratory depression (eg, benzodiazepines [unless used with extreme caution], particularly in patients who are already CO 2 retainers) or sedation; chosen drugs should have minimal other adverse eff ects. 76 Moreover, SSRIs may also be associated with troublesome adverse eff ects during treatment initiation, such as gastrointestinal upset, headache, tremor, psychomotor activation, and sedation 76 ; in addition, dry mouth is an adverse eff ect associated with both SSRI treatment and several inhaled therapies, so may be particularly problematic in patients with COPD. 91, 92 Currently, data are particularly scarce for the management of anxiety in patients with COPD, with inconclusive or contradictory fi ndings reported for SSRIs, azapirones (including buspirone), and tricyclic antidepressants. 76 In addition to monitoring adherence to COPD therapies, primary care practitioners should carefully monitor patients treated with antidepressants and anxiolytics for adherence. A meta-analysis of 18,245 individuals with chronic diseases showed that depressed patients had a 76% signifi cantly higher risk of nonadherence to medication compared with those without depressive symptoms. 93 Targeting dyspnea is key to the management of anxiety and depression in COPD, as breathlessness is frequently associated with the onset of both comorbidities. 21, 22 Th erapeutic approaches to alleviating dyspnea include PR, optimizing respiratory mechanics and muscle function (with bronchodilator therapy), and reducing central neural drive to respiratory muscles with supplemental oxygen or opioid medication. 94 Although bronchodilator therapy for COPD has not been shown to have signifi cant direct eff ects on depression or anxiety, 95 it can be assumed that the benefi cial eff ects on dyspnea are likely to alleviate associated emotional and mood symptoms.
Further research into eff ective screening, diagnosis, and management of comorbid anxiety and depressive disorders in COPD is warranted, including evaluation of a broad range of nonpharmacologic and drug-based interventions, alone and in combination. 76 
Conclusions
Anxiety and depression are common, yet frequently overlooked, comorbidities in COPD. Th e impact of these psychologic comorbidities is signifi cant; their consequences are evident in morbidity and mortality data, as well as in patientreported outcomes. As key points of contact for patients with COPD, it is essential that primary care practitioners are vigilant in monitoring for anxiety and depression in their patients with COPD, making the most of the available tools that can support them in doing so, and maintain an ongoing line of communication with other members of the multidisciplinary team. Treatment of anxiety and depression in COPD should adopt a holistic approach that incorporates both nonpharmacologic and pharmacologic interventions. However, the impact of eff ective screening, diagnosis, and management of anxiety and depression on COPD burden in patients requires further investigation.
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